MBX vs MIRM Stock Comparison
MBX currently leads MIRM in this stock comparison, with AIQ scores of 68 vs 53. The clearest difference is quality.
What is the main difference between MBX and MIRM?
MBX leads the current stock comparison as MBX Biosciences, Inc. Common Stock, with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
MBX Biosciences, Inc. Common Stock vs Mirum Pharmaceuticals, Inc.
MBX leads
MBX leads by 15 AIQ points, primarily on Quality and Momentum, but the lead has narrowed from 21 points over 30 sessions.
Stable: 3 of 5 evidence groups support MBX, its lead is narrowing, and its signal state is cleanly positive.
MBX Biosciences, Inc. Common Stock
Mirum Pharmaceuticals, Inc.
The Algovestiq AIQ Score currently favors MBX over MIRM, 68 versus 53 as of Nov 15, 2026. MBX's advantage is driven primarily by stronger quality and momentum. MBX also shows the weaker technical structure relative to its 50-day moving average. 3 of 5 covered evidence groups favor MBX today, and the comparison is rated Stable on stability: the leader's advantage has been narrowing. MBX lead: Weakening — the AIQ differential moved from 21 to 15 points over 30 sessions.
Compare MBX Biosciences, Inc. Common Stock and Mirum Pharmaceuticals, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare MBX and MIRM against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Quality74 vs 52MBX +22
- Momentum71 vs 54MBX +17
- Risk Resilience50 vs 51Even
3 of 5 evidence groups favor MBX. MBX’s edge is concentrated in quality and momentum.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Momentum +3
New signals
- Accumulation Pattern — bullish, volume, medium horizon (1.59x)
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- MACD Histogram Expanding Bullish — bullish, momentum, short horizon
Largest factor move: Momentum +2
No signal started or stopped since the prior session; its 4 active signals are unchanged.
MBX's lead was unchanged in the latest session.
Deeper signal detail for each name lives on its own signals page — MBX and MIRM both carry a full feed there.
The central trade-off
MBX (MBX Biosciences, Inc. Common Stock): the stronger current systematic profile, led by quality and momentum.
MIRM (Mirum Pharmaceuticals, Inc.): the counter-case, on fundamentals.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
MBXMBX on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
MIRMMIRM on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
MBXMBX on the Momentum factor, by 17 points.
Lower downside
MIRMMIRM carries the lower 1-month annualized volatility.
Analyst upside
MBXMBX on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | MBX | MIRM | Note |
|---|---|---|---|
| Implied upside to target | +90.7% | +66.9% | MBX has more room |
| Target dispersion | +61.9% | +45.9% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 12 | 14 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 5 covered evidence groups favor MBX. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | MBX | 68 vs 53 |
| Fundamentals | MIRM | EPS growth -65.4% vs 41.5%; TTM ROE -13.2% vs 75.2% |
| Valuation | Not covered | Not covered |
| Technicals | MBX | Price vs 50-day 0.3% vs 5.9%; vs 200-day 20.8% vs -4.5% |
| Risk Resilience | Even | Risk Resilience 50 vs 51 |
| Analyst expectations | MBX | Target upside 90.7% vs 66.9% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of MBX and MIRM and are excluded from the count.
AIQ Decision Stability
The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.
- The AIQ gap is wide at 15 points. (supports the conclusion holding)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader's signal state is cleanly positive. (supports the conclusion holding)
- Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on MBX.
How the comparison changed
120 daily snapshots · May 27 – Nov 13MBX lead: Weakening — the AIQ differential moved from 21 to 15 points over 30 sessions.
- Today
- MBX +15
- 68 vs 53
- 7 sessions ago
- MBX +17
- 67 vs 50
- 30 sessions ago
- MBX +21
- 68 vs 47
- 90 sessions ago
- MBX +22
- 75 vs 53
The lead changed hands once in this window, most recently on Jun 8 when MBX moved ahead of MIRM.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
7 bullish / 0 bearish / 2 neutral
Only MBX
- Golden Cross Active — bullish, trend, long horizon (20.41%)
- ADX Trend Weakening — neutral, trend, medium horizon
- Accumulation Pattern — bullish, volume, medium horizon (1.59x)
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- MACD Histogram Expanding Bullish — bullish, momentum, short horizon
- Price Reclaimed 50-Day MA — bullish, trend, medium horizon
- TSI Bullish Crossover — bullish, momentum, short horizon
- Uptrend Structure Active — bullish, trend, long horizon
1 bullish / 2 bearish / 1 neutral, conflicted
Only MIRM
- Death Cross Active — bearish, trend, long horizon (10.83%)
- Low Volume Rally Warning — bearish, volume, short horizon (0.54x)
- TRIX Bullish Signal — bullish, momentum, short horizon
Both carry 1 more signal that do not separate them: ATR Expansion - Breakout Mode.
MIRM is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price and the AIQ Score both moved up over the latest session (price +2.62%, AIQ +1 points).
Price and the AIQ Score both moved up over the latest session (price +0.71%, AIQ +1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1MIRM closes the Quality gap — currently 22 points behind, the largest single contributor to MBX's edge.
- 2MIRM's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3MBX's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
- 4The narrowing continues — the lead has already given back 6 points over 30 sessions, and a further 15-point move would eliminate MBX's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
MIRM leads on balance| Metric | MBX | MIRM |
|---|---|---|
| Revenue growth (YoY) | 0% | 5.4% |
| EPS growth (YoY) | -65.4% | 41.5% |
| Gross margin | 0% | 81.7% |
| Operating margin | 0% | -25.3% |
| Return on equity (TTM) | -13.2% | 75.2% |
| Debt to equity | 0.01 | -13.72 |
Performance
MBX leads 4 of 6 windows| Metric | MBX | MIRM |
|---|---|---|
| 1 week (5 sessions) | 8.9% | 0.3% |
| 1 month (20 sessions) | 12.8% | 17.3% |
| 3 months (63 sessions) | -18% | -5.8% |
| 6 months (126 sessions) | 72.4% | -8% |
| Year to date | 77.4% | 19% |
| 1 year (252 sessions) | 127.4% | 32.8% |
Technicals
MBX has the stronger structure| Metric | MBX | MIRM |
|---|---|---|
| RSI (14) | 53.3 | 59.9 |
| ADX (14) | 13.7 | 26.1 |
| Price vs 50-day | 0.3% | 5.9% |
| Price vs 200-day | 20.8% | -4.5% |
| Volatility (1M, annualized) | 68.2% | 50.6% |
Risk
Split| Metric | MBX | MIRM |
|---|---|---|
| Beta | 1.26 | 1.07 |
| Sharpe ratio | 1.42 | 0.79 |
| Sortino ratio | 2.43 | 1.12 |
| Max drawdown | -37.6% | -38.4% |
| Current drawdown | -20.9% | -26.9% |
| Annualized volatility | 77.3% | 48.6% |
| Value at risk (95%) | -7.1% | -4.9% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, MBX or MIRM?
On the Algovestiq AIQ Score, MBX is the stronger of the two as of Nov 15, 2026, scoring 68 against MIRM's 53. The edge comes from quality and momentum. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is MBX or MIRM the better buy right now?
MBX carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Stable — 3 of 5 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.
Why does the AIQ Score favor MBX over MIRM?
The composite weights Quality, Value, Momentum and Risk Resilience. MBX leads Quality by 22 points; MBX leads Momentum by 17 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, MBX or MIRM?
Analyst price targets imply +90.7% upside for MBX and +66.9% for MIRM, so the Street currently favors MBX. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, MBX or MIRM?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, MBX or MIRM?
MIRM on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, MBX or MIRM?
MBX on the Momentum factor, by 17 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, MBX or MIRM?
MIRM is the more resilient of the two, so the other name carries the higher downside risk. MIRM carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is MBX more profitable than MIRM?
MIRM leads on the comparable margin measures — gross margin 0% vs 81.7%; operating margin 0% vs -25.3%; ttm roe -13.2% vs 75.2%.
Is MBX's lead over MIRM getting stronger or weaker?
MBX lead: Weakening — the AIQ differential moved from 21 to 15 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands once in that window, most recently on 2026-06-08, when MBX moved ahead of MIRM.
What would change the MBX vs MIRM verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: MIRM closes the Quality gap — currently 22 points behind, the largest single contributor to MBX's edge; MIRM's Death Cross Active resolves — a bearish trend rule currently active against it; MBX's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; the narrowing continues — the lead has already given back 6 points over 30 sessions, and a further 15-point move would eliminate MBX's advantage entirely.
What do the current signals say about MBX and MIRM?
MBX: 7 bullish / 0 bearish / 2 neutral. MIRM: 1 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on MBX is Golden Cross Active (bullish, long horizon). On MIRM it is Death Cross Active (bearish, long horizon).
Compare MBX and MIRM with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.